Illustrative image.
STRIBILD
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate
$4215.00
3 × 30 tablets · 3 months supply
BrandBranded medicine· By Gilead Sciences
$1405.00 per month
How long a supply?
Test mode: no payment is taken. View cart
Annual cost
$16860a year at this pack size
Prescription required
Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.
FDA boxed warningPosttreatment acute exacerbation of hepatitis b
Severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued EMTRIVA or VIREAD, which are components of STRIBILD. Hepatic function should be monitored closely, with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue STRIBILD. If appropriate, initiation of anti-hepatitis B therapy may be warranted
Severe acute exacerbations of hepatitis B have been reported in patients coinfected with HIV-1 and HBV who have discontinued EMTRIVA or VIREAD, two of the components of STRIBILD. Hepatic function should be monitored closely in these patients. If appropriate, initiation of anti-hepatitis B therapy may be warranted.
About STRIBILD
Overview
Stribild is a prescription tablet containing elvitegravir, cobicistat, emtricitabine and tenofovir disoproxil fumarate. It is a complete treatment for HIV-1 infection in adults and children aged 12 years and older who weigh at least 35 kg. It is used in people who have not previously received HIV treatment, or to replace a stable regimen used for at least six months when HIV-1 levels are below 50 copies/mL, with no previous treatment failure or known resistance to its components. Three ingredients block enzymes HIV needs to multiply, while cobicistat boosts elvitegravir.
What it treats
Treatment of HIV-1 infection in adults and children aged 12 years and older weighing at least 35 kg, as a complete treatment regimen for those who: • Have not previously received antiretroviral treatment; or • Are switching from a stable antiretroviral regimen used for at least 6 months, with HIV-1 RNA below 50 copies/mL, no history of treatment failure and no known resistance mutations to any STRIBILD component.
Safety information
Side effects
Common side effects of STRIBILD are nausea and diarrhea, each reported in at least 10% of patients. Contact your doctor if you develop side effects or concerns that could indicate a serious reaction. Serious risks include new or worsening kidney problems, including acute kidney failure and Fanconi syndrome, a kidney disorder; lactic acidosis (a buildup of lactic acid in the blood); severe liver enlargement with fat buildup; and bone loss or problems with bone mineralization. Severe flare-ups of hepatitis B can occur in people who have both HIV-1 and hepatitis B. Immune reconstitution syndrome, involving changes in the immune response, may require further evaluation and treatment. Interactions with other medicines can cause serious adverse effects, make treatment less effective, or lead to HIV resistance. Tell your doctor about all medicines you use, including any recent use of medicines that can harm the kidneys.
FDA boxed warning
Posttreatment acute exacerbation of hepatitis b
Severe acute exacerbations of hepatitis B have been reported in patients who are coinfected with HIV-1 and HBV and have discontinued EMTRIVA or VIREAD, which are components of STRIBILD. Hepatic function should be monitored closely, with both clinical and laboratory follow-up for at least several months in patients who are coinfected with HIV-1 and HBV and discontinue STRIBILD. If appropriate, initiation of anti-hepatitis B therapy may be warranted
Severe acute exacerbations of hepatitis B have been reported in patients coinfected with HIV-1 and HBV who have discontinued EMTRIVA or VIREAD, two of the components of STRIBILD. Hepatic function should be monitored closely in these patients. If appropriate, initiation of anti-hepatitis B therapy may be warranted.
A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.
When to call your doctor
If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.
Before taking this medicine
Do not take STRIBILD with alfuzosin; carbamazepine, phenobarbital or phenytoin; rifampin; lurasidone or pimozide; dihydroergotamine, ergotamine or methylergonovine; St. John’s wort; lomitapide, lovastatin or simvastatin; sildenafil used as Revatio for pulmonary arterial hypertension; triazolam; or oral midazolam. These combinations can cause serious or life-threatening adverse effects, or reduce STRIBILD’s effectiveness and lead to resistance. Other medicines may also interact, so all medicines and herbal products should be reviewed before use. STRIBILD can cause new or worsening kidney problems, including acute kidney failure and Fanconi syndrome. Avoid use with medicines that can damage the kidneys, including recently used medicines. Treatment must be stopped if symptoms or laboratory findings suggest lactic acidosis or serious liver toxicity, including severe liver enlargement with fat accumulation. Caution is needed in people with a history of fractures related to weakened bones or other risk factors for osteoporosis or bone loss; bone density monitoring may be considered. Immune reconstitution syndrome may require further assessment and treatment. STRIBILD is not recommended during pregnancy and should not be started in pregnant individuals because exposure to cobicistat and elvitegravir is substantially reduced during pregnancy. Breastfeeding is not recommended because of the potential for HIV transmission. STRIBILD is not recommended for children under 12 years of age or anyone weighing less than 35 kg.
Interactions
STRIBILD is a complete HIV-1 treatment regimen and should not be taken with other antiretroviral medicines used to treat HIV-1. STRIBILD can change blood levels of medicines broken down by the liver enzymes CYP3A or CYP2D6. Medicines that increase CYP3A activity can change blood levels of one or more ingredients in STRIBILD. Ask your doctor to check for interactions with your other medicines before and during treatment.
Using STRIBILD
Dosing
Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.
Storage
Store below 25°C in a dry place, in the original pack, away from direct light and moisture. Do not keep it in a bathroom. Keep all medicines out of the sight and reach of children.
Clinical information on this page is summarised from the US FDA label STRIBILD (ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE) TABLET, FILM COATED [GILEAD SCIENCES, INC.] (DailyMed, retrieved 19 September 2026).
Reviews
No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.
- Every prescription order is checked by a licensed pharmacist before dispensing.
- Payment pages are encrypted and card details never reach our servers.
- We ship internationally, with cold-chain packing where a medicine needs it.
Related medicines
Ziagen
Abacavir
By GSK
Tablets · from 60 per pack
Also for antivirals
Brand $767.00
Baraclude
Enetecavir
By Bristol Myers
Tablets · from 30 per pack
Also for antivirals
Brand from $1,203.00
Isenrtess
Raltegravir
By MSD
Tablets · from 60 per pack
Also for antivirals
Brand $1,398.00
Incivek
Telaprevir
By Janssen Cilag
Tablets · from 168 per pack
Also for antivirals
Brand $22,641.00